A rumor regarding Crispr Therapeutics (CRSP) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Shares of Crispr are up $1.14, or 2%, to $53.67 in morning trading.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics call volume above normal and directionally bullish
- Cathie Wood Sells Tesla (TSLA) and SoFi Stocks, Makes a $34M Bet on This USDC Giant
- Crispr Therapeutics price target lowered to $77 from $87 at Citi
- Promising Outlook for Crispr Therapeutics AG: Buy Rating Backed by Strong Product Launches and Strategic Developments
- CRISPR Therapeutics Reports Q3 2025 Financial Results